Enhanced anticancer activity of 5-FU in combination with Bestatin: Evidence in human tumor-derived cell lines and an H22 tumor-bearing mouse

Drug Discoveries & Therapeutics
Jin LiWenfang Xu

Abstract

The clinical use of 5-fluorouracil (5-FU) is increasingly limited by low response rates, adverse reactions, and toxicity. A drug combination offers a new strategy for appropriate use of 5-FU. Bestatin, an aminopeptidase N (APN) inhibitor, has been used as an adjuvant chemotherapy drug because of its actions to suppress tumorigenesis and invasion. The current study evaluated the anticancer efficacy of 5-FU plus Bestatin at the cellular and animal level. The combination killed more colonic cancer, hepatic carcinoma, and ovarian cancer cells and fewer nonmalignant human embryonic kidney (HEK293) and Chinese hamster ovary (CHO) cells than 5-FU or Bestatin alone. Moreover, 41.58% of ES-2 and 20.86% of PLC/PRF/5 cell apoptosis was caused by the combination of the two, while 5-FU caused apoptosis of 20.86% of ES-2 cells and 8.85% of PLC/PRF/5 cells. The cell cycle was arrested in the S and G0/G1 phases when a combination of the two was used. In an experiment involving mice bearing tumors, a combination of the two had a rate of tumor inhibition of 61.98%, while 5-FU alone had a rate of tumor inhibition of just 49.17%. In addition, the combination of the two was safer than either drug alone and did not cause weight loss or death. In con...Continue Reading

References

May 1, 1996·Immunopharmacology·A PapapetropoulosJ D Catravas
Mar 31, 1999·Immunology Today·D RiemannJ Langner
Jan 7, 2000·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·S GiacchettiF Lévi
Mar 23, 2002·Free Radical Biology & Medicine·Beate FirlaUwe Lendeckel
Jun 25, 2002·European Journal of Pharmacology·Jean-Michel BenoistDaniel Le Bars
Apr 17, 2003·Journal of the National Cancer Institute·Yukito IchinoseUNKNOWN NK421 Lung Cancer Surgery Group
Jun 18, 2003·Annals of Oncology : Official Journal of the European Society for Medical Oncology·J-Y DouillardE Van Cutsem
Oct 11, 2005·Medicinal Research Reviews·Brigitte Bauvois, Daniel Dauzonne
Aug 30, 2006·Proceedings of the National Academy of Sciences of the United States of America·Anthony AddlagattaBrian W Matthews
Mar 10, 2007·Current Medicinal Chemistry·Yepeng Luan, Wenfang Xu
Jul 8, 2008·Trends in Molecular Medicine·Paola Mina-Osorio
Aug 11, 2010·The Journal of Clinical Investigation·Naotsugu HaraguchiMasaki Mori
Apr 12, 2011·Hepatology : Official Journal of the American Association for the Study of Liver Diseases·Bruno ChristMatthias M Dollinger
Feb 7, 2012·Proceedings of the National Academy of Sciences of the United States of America·Liliana Guzman-RojasRenata Pasqualini
Aug 16, 2012·Journal of Hepato-biliary-pancreatic Sciences·Hiroaki NaganoMasaki Mori

❮ Previous
Next ❯

Citations

Jun 21, 2016·European Journal of Medicinal Chemistry·Yuqi JiangYingjie Zhang
Sep 28, 2018·Frontiers in Pharmacology·Jian ZhangXuejian Wang

❮ Previous
Next ❯

Related Concepts

Related Feeds

Apoptosis in Cancer

Apoptosis is an important mechanism in cancer. By evading apoptosis, tumors can continue to grow without regulation and metastasize systemically. Many therapies are evaluating the use of pro-apoptotic activation to eliminate cancer growth. Here is the latest research on apoptosis in cancer.

Apoptosis

Apoptosis is a specific process that leads to programmed cell death through the activation of an evolutionary conserved intracellular pathway leading to pathognomic cellular changes distinct from cellular necrosis